| Trial ID: | L6888 |
| Source ID: | NCT02285205
|
| Associated Drug: |
Oral Administration Of Lobeglitazone
|
| Title: |
A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Non-alcoholic Fatty Liver Disease
|
| Interventions: |
DRUG: Oral administration of Lobeglitazone
|
| Outcome Measures: |
Primary: changes from baseline in controlled attenuation parameters (CAP), Changes from baseline in controlled attenuation parameters (CAP) measured by transient elastography (fibroscan) after treatment with Lobeglitazone, 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Yonsei University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
38
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-11
|
| Completion Date: |
2015-11
|
| Results First Posted: |
|
| Last Update Posted: |
2016-02-02
|
| Locations: |
Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 120-752, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02285205
|
